| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Mardi C. Dier has resigned from her position as Chief Financial Officer and Chief Business Officer of ACELYRIN, Inc. (the “Company”) through mutual agreement between the Company and Ms. Dier. Her last day of employment with the Company will be August 15, 2023 (the “Resignation Date”). In connection therewith, the Company has entered into a Separation Agreement and Mutual General Release with Ms. Dier (the “Resignation Agreement”), pursuant to which the Company agreed to provide Ms. Dier with certain severance benefits, including the following: one year of her current base salary and COBRA health insurance premiums, a lump sum payment equal to 50% of her target bonus as pro-rated through the Resignation Date, and nine months of stock option award vesting acceleration with respect to her outstanding stock option awards. The foregoing description of the Resignation Agreement does not purport to be complete and is subject to, and qualified in its entirety by reference to, the full text of the Resignation Agreement which is filed as Exhibit 10.1 hereto and is incorporated by reference.
In connection with Ms. Dier’s resignation, the Company appointed Gil Labrucherie as the Company’s Chief Financial Officer on an interim basis, effective as of August 2, 2023, while the Company conducts a search for a permanent Chief Financial Officer. In such role, Mr. Labrucherie will serve as the Company’s principal financial officer and principal accounting officer. Prior to consulting, Mr. Labrucherie, age 52, served as Chief Financial Officer of the Company from July 2022 until November 2022 when he stepped down for personal family reasons. From June 2016 until July 2022, Mr. Labrucherie served as Chief Financial Officer for Nektar Therapeutics, and added the role of Chief Operating Officer of Nektar Therapeutics in October 2019. Mr. Labrucherie received his J.D. from the Berkeley Law School, his B.A. from the University of California, Davis and holds the Certified Financial Analyst designation from the CFA Institute. There are no arrangements or understandings between Mr. Labrucherie and any other person related to Mr. Labrucherie’s appointment as the Company’s interim Chief Financial Officer. There is no family relationship between Mr. Labrucherie and any director, executive officer, or person nominated or chosen by the Company to become a director or executive officer of the Company.
Pursuant to a master consulting agreement between the Company and Mr. Labrucherie, Mr. Labrucherie will receive cash compensation of $500 per hour. Mr. Labrucherie has also entered into the Company’s standard form of indemnification agreement, a copy of which was filed as Exhibit 10.10 to the Company’s Registration Statement on Form S-1, filed with the Securities and Exchange Commission on May 1, 2023. A copy of the master consulting agreement between Mr. Labrucherie and the Company will be filed as an exhibit to the Company’s quarterly report on Form 10-Q for the quarter ending September 30, 2023.
| Item 9.01 | Financial Statements and Exhibits. |
